InterWest Partners

InterWest operates through dedicated sector teams with significant independence. The general partners managing enterprise, healthcare, and deep-tech practices make investment decisions within their domains. The firm has historically functioned as a partnership where senior investors lead deal sourcing, diligence, and board representation.

InterWest relies on four decades of founder relationships, academic ties to Stanford and UC life-science departments, and its position in the Sand Hill Road network. Its multi-sector structure allows it to see deals that pure-play tech or healthcare funds might miss. The firm has long argued that deep domain partners, not junior scouts, drive origination.

InterWest primarily makes direct venture investments into private companies. The firm does not market itself as a fund-of-funds and has built its reputation on direct equity and board-level engagement with portfolio companies.

The firm invests from seed-stage rounds through growth equity. In healthcare, InterWest has backed pre-clinical biotech companies and series-stage digital health platforms. In enterprise, it has written first checks into AI infrastructure and later-stage SaaS companies. This flexibility has been a consistent feature across its fund families.

InterWest has not historically invested in consumer internet, gaming, crypto, or traditional energy extraction. The firm concentrates exclusively on enterprise technology, healthcare and life sciences, and industrial technology.

InterWest is a traditional venture capital partnership, not a single-family office or a corporate venture arm. It raises blind-pool funds from institutional limited partners — typically endowments, foundations, and pension funds — and deploys capital through sector-specialist general partners operating within a single firm.

InterWest was among the earliest Sand Hill Road firms to run parallel healthcare and IT practices under one roof. This structure gave it access to biotech and diagnostics deals at a time when most VC firms treated life sciences as a separate asset class. Portfolio companies have included surgical robotics, genomics, and medical-device businesses alongside enterprise-software platforms.